自1966年Lipson等首次报道使用光敏剂血叶啉衍生物(HPD)与氙弧光灯光源照射用于人体癌症的诊治后,至今仍沿用HPD作为光辐射疗法(PRT)的光敏剂。HPD为一种含多种卟啉成分的混合物,除含有活性成分外,还含有无效成分和易导致人体皮肤光敏副作用的成分。鉴于HPD的光敏效应还不够理想,故从血卟啉中分离、提取新光敏剂的工作一直在研究中,如1981年Doug- Since 1966, Lipson et al. first reported the use of photosensitizer hemosiderin derivative (HPD) and xenon arc light source irradiation for the treatment of human cancer, HPD has still been used as a photosensitizer for photoradiotherapy (PRT). HPD is a mixture containing a variety of porphyrin components, in addition to active ingredients, it also contains inactive ingredients and ingredients that can easily cause the skin’s photosensitive side effects. In view of the fact that the photosensitive effect of HPD is not ideal enough, the work of separating and extracting new photosensitizers from hematoporphyrins has been under research, such as Doug-